Quercetin is an antioxidant, detox, and anti-inflammatory agent, which may help lower inflammation as well as reduce toxic effects. It has been argued that vaccines have potential risks of local and systemic inflammatory responses and toxic effects of synthetic…

Several months ago, an outbreak of pneumonia of unknown aetiology was detected in Wuhan City (China) and the aetiological agent of the atypical pneumonia was isolated by the Chinese authorities as novel coronavirus (2019-nCoV or SARS-CoV-2). The WHO announced…

COVID-19 is an emerging disease that is a major threat to the global community. The main challenge in this disease is the lack of proper or proven medication. The drugs used to treat this disease are only for symptomatic treatment. Studies of other coronaviruses…

Quercetin, a naturally occurring dietary flavonoid, is well known to ameliorate chronic diseases and aging processes in humans, and its antiviral properties have been investigated in numerous studies. In silico and in vitro studies demonstrated that quercetin…

QP is a safe agent and in combination with standard care, when used in early stage of viral infection, could aid in improving the early symptoms and help in preventing the severity of COVID-19 disease. It is suggested that a double-blind, placebo-controlled…

QP statistically shortens the timing of molecular test conversion from positive to negative, reducing at the same time symptoms severity and negative predictors of COVID-19.

Hitting the TMPRSS2 receptor likely solves the Covid-19 pandemic. A nice, in silico study to find the best TMPRSS2 inhibition candidates. Familiar names come on top: Camostat, Quercetins, Catechins. arxiv.org/abs/2108.13764

Powerful combo of TMPRSS2 inhibitor Nafamostat and Interferon-α performs strongly in vitro and in vivo against Sars-Cov-2. Nafamostat looks again superior to Camostat here. Hitting TMPRSS2 is critical. mdpi.com/1999-4915/13/9…

SARS-CoV-2 and its vaccine/immune-escaping variants continue to pose a serious threat to public health due to a paucity of effective, rapidly deployable, and widely available treatments. Here, we address these challenges by combining Pegasys (IFNα) and nafamostat…

The CDC has rejected Xlear's requests, saying one of the studies the company offered "presents no hard evidence ...in terms of viral load reduction."

About Geert Vanden Bossche https://www.linkedin.com/in/geertvandenbossche More in https://www.facebook.com/groups/204568537437863/?ref=share

The emergence and rapid rise in prevalence of three independent SARS-CoV-2 "501Y lineages", B.1.1.7, B.1.351 and P.1, in the last three months of 2020 prompted renewed concerns about the evolutionary capacity of SARS-CoV-2 to adapt to both rising population…